Chargement en cours...
Current clinical evidence on pioglitazone pharmacogenomics
Pioglitazone is the most widely used thiazolidinedione and acts as an insulin-sensitizer through activation of the Peroxisome Proliferator-Activated Receptor-γ (PPARγ). Pioglitazone is approved for use in the management of type 2 diabetes mellitus (T2DM), but its use in other therapeutic areas is in...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3840328/ https://ncbi.nlm.nih.gov/pubmed/24324437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2013.00147 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|